

FIGURE 1A. Drug Screening Report for TBT, Lot ARB-ID#99-332

VEHICLE	634 µg /ml in EtOH			UNIT mg
LOT #1		TRIAL #1		
HSV-1 (HFF Cells)				
CPE Inhibition – MCG/ML				
09/17/98	EC50 >10	CC50 >10	SI = 0	ACV EC50 = 1.2
Plaque Reduction – MCG/ML				
10/19/98	EC50 = 5.9	CC50 >10	SI >1.6	ACV EC50 = 0.3
HSV-2 (HFF Cells)				
CPE Inhibition – MCG/ML				
09/17/98	EC50 = 2.0	CC50 >10	SI >6.0	ACV EC50 = 1.9
Plaque Reduction – MCG/ML				
10/19/98	EC50 = 0.9	CC50 >10	SI >11.1	ACV EC50 = 0.1
HCMV (HFF Cells)				
CPE Inhibition – MCG/ML				
10/01/98	EC50 = 5.0	CC50 >10	SI >2.0	GCV EC50 = 0.06
Plaque Reduction – MCG/ML				
/ /	EC50	CC50	SI	GCV EC50
MCMV (HFF Cells)				
Plaque Reduction – MCG/ML				
/ /	EC50	CC50	SI	CCV EC50
VZV (HFF Cells)				
CPE Inhibition – MCG/ML				
/ /	EC50	CC50	SI	ACV EC50
Plaque Reduction – MCG/ML				
/ /	EC50	CC50	SI	CCV EC50

Cytopathic Effect Inhibition and Plaque Reduction Assays For HSV-1, HSV-2, HCMV, MCMV, and VSV, in HFF cell cultures.

FIGURE 1B. Drug Screening Report for TBT, Lot ARB-ID#99-332

EBV				
VCA – MCG/ML (In Daudi Cells)				
10/16/98	EC50 = 1.4	CC50 = 0.21	SI = 0	ACV EC50 = 1.8
EBV DNA – MCG/ML (In Daudi Cells)				
/ /	EC50	CC50	SI	ACV EC50
Toxicity Assays				
Neutral Red Uptake – MCG/ML (In Stationary HFF Cells)				
09/17/98	CC50 >10	ACV IC50 >100	GCV IC50 >100	
Cell Proliferation – MCG/ML (In Rapidly Growing Daudi Cells)				
10/16/98	IC50 <0.08		ACV IC50 >50	
Cell Proliferation – MCG/ML (In Rapidly Growing HFF Cells)				
10/16/98	IC50 0.02	ACV IC50 >100	GCV IC50 40.0	
Comments and Recommendations: HCMV PR. This compound is problematic.				

Cytopathic Effect Inhibition and Plaque Reduction Assays EBV in DAUDI cell cultures;
Toxicity Assays in HFF and DAUDI cell cultures.

EBV DNA – MCG/ML (In Daudi Cells)

FIGURE 2. HSV ELISA METHOD

1. Remove the growth media HFF cells.
2. Add 100 μ l of MEM to the 6 cell control wells.
3. Add 50 μ l of the diluted virus to the remaining wells.
 - A. Herpes simplex virus type 1, ATCC # V-733, strain F. HSV-1 (5/3/96), one plate. Dilute stock 1:2000, 2.0 μ l in 4.0 ml MEM.
 - B. Herpes simplex virus type 2, ATCC # VR-734, strain G. HSV-2 (5/3/96), one plate. Dilute stock 1:2000, 2.0 μ l + 4.0 ml MEM.

Clinical strains.

1. Specimen # 1. HSV-1, December 9, 1997, eye. Dilute stock 1:500, 8.0 μ l plus 4.0 ml of MEM.
2. Specimen # 2, HSV-1, September 30, 1997, oral pharynx. Dilute stock 1:50, 60 μ l plus 3.0 ml of MEM.
3. Specimen # 3, HSV-2, Nov. 26, 96, oral pharynx. Dilute stock 1:500, 8.0 μ l plus 4.0 ml of MEM.
4. Specimen # 4, HSV-2, Dec. 27, 96, ETT. Dilute stock (May 27, 98) 1:100, 40.0 μ l plus 4.0 ml of MEM.
5. Specimen # 5. HSV-2, April 11, 1998, penis. Dilute stock 1:100, 40 μ l plus 4.0 ml of MEM.
6. Specimen # 6. HSV-2, April 24, 1998. Dilute stock 1:100, 40 μ l plus 4.0 ml of MEM.
4. Add the virus to the plates for one hour and incubate the plates at 37° C.
5. Remove the virus inoculum and add 100 μ l of MEM to the virus control wells and add 100 μ l of diluted drug to each of the remaining wells.

TBT. Stock TBT contains 624 μ g/ml of active component, 10-deacetyl-7-xylosyltaxol in 50% ethanol from Rainbow Research, Inc.

- a. Warm the TBT and 1X MEM to 37° C. The stock TBT was diluted to 4.0 μ g/ml by adding 154 μ l of TBT to 24,000 μ l of 1X MEM.

TBT, μ g/ml	4.0	3.0	2.0	1.0	0.75	0.5	0.25	0.1
Vol. Of extract, μ l.	6000	6000	4000	2000	1500	1000	500	200
MEM, μ l.	-	2000	4000	6000	6500	7000	7500	7800

ELISA RESULTS:

Antibody to HSV-1 was used at a 1:2000 dilution. Antibody to HSV-2 was used at a 1:1500 dilution. Read with dual wavelength, 630 – 490 nm.

FIGURE 3

HSV-1 ELISA CONTROL (ATCC VR-733, STRAIN F)

CC	VC	4	3	2	1	0.75	0.5	0.25	0.1	µg/ml
0.000	0.361	0.069	0.129	0.188	0.373	0.360	0.367	0.309	0.305	
0.000	0.231	0.046	0.093	0.236	0.349	0.357	0.329	0.352	0.362	
0.000	0.304	0.052	0.114	0.206	0.358	0.327	0.291	0.355	0.354	
0.000	0.295	0.033	0.097	0.247	0.338	0.354	0.306	0.316	0.381	
0.000	0.290	0.039	0.098	0.241	0.312	0.301	0.347	0.346	0.361	
0.000	0.303	0.045	0.065	0.203	0.344	0.349	0.333	0.362	0.346	
0.000	0.297	0.047	0.099	0.220	0.346	0.341	0.329	0.340	0.352	
	0.297	0.047	0.099	0.220	0.346	0.341	0.329	0.340	0.352	
		15.9	33.4	74.0	116.3	114.8	110.6	114.3	118.2	
DATE: 6/24/98					INOC: 6/22/98					
DRUG: TBT					VIRUS: HSV-1					
					Control TBT-IC50 = 3 µg/ml					

Column headings for the ELISA are culture control (CC) representing uninfected cell culture; Viral Control (VC), representing infected cell culture; 4-3-2-1-0.75-0.5-0.25-0.1 are viral infected cell cultures to which 4 to 0.1 µg/ml Taxus Brevifolia Tincture (TBT) has been added.

20030323 15:00

FIGURE 4
HSV-1 ELISA, CLINICAL SPECIMEN #1

CC	VC	4	3	2	1	0.75	0.5	0.25	0.1	µg/ml
0.000	0.387	0.147	0.155	0.157	0.331	0.256	0.319	0.272	0.368	
0.000	0.279	0.107	0.166	0.161	0.273	0.235	0.258	0.238	0.370	
0.002	0.256	0.109	0.115	0.203	0.289	0.187	0.258	0.245	0.368	
0.000	0.328	0.110	0.135	0.216	0.295	0.251	0.231	0.274	0.370	
0.005	0.328	0.102	0.142	0.249	0.327	0.318	0.294	0.366	0.314	
0.003	0.344	0.098	0.198	0.204	0.316	0.311	0.324	0.374	0.362	
0.002	0.320	0.112	0.152	0.198	0.305	0.260	0.281	0.295	0.359	
	0.319	0.111	0.150	0.197	0.304	0.258	0.279	0.293	0.357	
		34.7	47.1	61.7	95.2	81.0	87.6	92.0	112.0	
DATE: 6/24/98					INOC: 6/22/98					
DRUG: TBT					VIRUS: HSV-1					
					Specimen #1 TBT-IC50 = 3 µg/ml					

Column headings for the ELISA are culture control (CC) representing uninfected cell culture; Viral Control (VC), representing infected cell culture; 4-3-2-1-0.75-0.5-0.25-0.1 are viral infected cell cultures to which 4 to 0.1 µg/ml Taxus Brevifolia Tincture (TBT) has been added.

FIGURE 5
HSV-1 ELISA, CLINICAL SPECIMEN #2

CC	VC	4	3	2	1	0.75	0.5	0.25	0.1	µg/ml
0.005	0.238	0.016	0.005	0.020	0.048	0.061	0.029	0.029	0.062	
0.002	0.086	0.005	0.019	0.050	0.053	0.054	0.080	0.080	0.056	
0.009	0.111	0.010	0.000	0.000	0.033	0.027	0.104	0.104	0.077	
0.006	0.141	0.034	0.011	0.022	0.065	0.059	0.059	0.059	0.109	
0.012	0.186	0.002	0.057	0.110	0.061	0.087	0.108	0.108	0.086	
0.006	0.196	0.018	0.039	0.017	0.031	0.087	0.090	0.090	0.120	
0.007	0.160	0.014	0.022	0.037	0.049	0.063	0.078	0.078	0.085	
	0.153	0.008	0.015	0.030	0.042	0.056	0.072	0.072	0.078	
		4.9	9.9	19.5	27.3	36.5	46.8	46.8	51.2	
DATE: 6/24/98					INOC: 6/22/98					
DRUG: TBT					VIRUS: HSV-1					
					Specimen #2 TBT-IC50 = 0.25 µg/ml					

Column headings for the ELISA are culture control (CC) representing uninfected cell culture; Viral Control (VC), representing infected cell culture; 4-3-2-1-0.75-0.5-0.25-0.1 are viral infected cell cultures to which 4 to 0.1 µg/ml Taxus Brevifolia Tincture (TBT) has been added.

FIGURE 6

Column headings for the ELISA are culture control (CC) representing uninfected cell culture; Viral Control (VC), representing infected cell culture; 4-3-2-1-0.75-0.5-0.25-0.1 are viral infected cell cultures to which 4 to 0.1 µg/ml *Taxus Brevifolia* Tincture (TBT) has been added.

FIGURE 7
HSV-2 ELISA, CLINICAL SPECIMEN #3

CC	VC	4	3	2	1	0.75	0.5	0.25	0.1	µg/ml
0.015	0.337	0.119	0.109	0.145	0.290	0.137	0.200	0.264	0.204	
0.008	0.266	0.109	0.105	0.168	0.167	0.129	0.124	0.249	0.248	
0.010	0.207	0.056	0.077	0.154	0.215	0.106	0.158	0.191	0.253	
0.015	0.213	0.079	0.134	0.141	0.171	0.155	0.288	0.183	0.165	
0.027	0.211	0.131	0.090	0.105	0.171	0.122	0.203	.0189	0.168	
0.007	0.217	0.070	0.080	0.059	0.139	0.132	0.110	0.125	0.145	
0.014	0.242	0.094	0.099	0.129	0.192	0.130	0.181	0.200	0.197	
	0.228	0.080	0.086	0.115	0.179	0.117	0.167	0.187	0.184	
		35.2	37.5	50.4	78.2	51.1	73.1	81.7	80.4	
DATE: 6/24/98					INOC: 6/22/98					
DRUG: TBT					VIRUS: HSV-2					
					Specimen #3 TBT-IC50 = 2.0 µg/ml					

Column headings for the ELISA are culture control (CC) representing uninfected cell culture; Viral Control (VC), representing infected cell culture; 4-3-2-1-0.75-0.5-0.25-0.1 are viral infected cell cultures to which 4 to 0.1 µg/ml Taxus Brevifolia Tincture (TBT) has been added.

FIGURE 8
HSV-2 ELISA, CLINICAL SPECIMEN # 4

CC	VC	4	3	2	1	0.75	0.5	0.25	0.1	µg/ml
0.012	0.190	0.026	0.021	0.059	0.089	0.018	0.066	0.115	0.148	
0.004	0.152	0.018	0.028	0.037	0.059	0.072	0.083	0.106	0.165	
0.030	0.199	0.001	0.042	0.033	0.026	0.052	0.065	0.073	0.195	
0.012	0.174	0.016	0.042	0.046	0.095	0.028	0.064	0.123	0.161	
0.020	0.224	0.033	0.048	0.027	0.031	0.025	0.100	0.078	0.229	
0.010	0.213	0.021	0.025	0.029	0.056	0.046	0.086	0.088	0.152	
0.015	0.192	0.019	0.034	0.039	0.059	0.040	0.077	0.097	0.175	
	0.177	0.005	0.020	0.024	0.045	0.026	0.063	0.083	0.160	
		2.5	11.1	13.4	25.2	14.4	35.3	46.5	90.4	
DATE: 6/24/98					INOC: 6/22/98					
DRUG: TBT					VIRUS: HSV-2					
					Specimen #4 TBT-IC50 = 0.25 µg/ml					

Column headings for the ELISA are culture control (CC) representing uninfected cell culture; Viral Control (VC), representing infected cell culture; 4-3-2-1-0.75-0.5-0.25-0.1 are viral infected cell cultures to which 4 to 0.1 µg/ml *Taxus Brevifolia* Tincture (TBT) has been added.

FIGURE 9
HSV-2 ELISA, CLINICAL SPECIMEN #5

CC	VC	4	3	2	1	0.75	0.5	0.25	0.1	µg/ml
0.016	0.220	0.041	0.026	0.052	0.121	0.134	0.109	0.159	0.104	
0.013	0.219	0.017	0.045	0.048	0.084	0.078	0.084	0.130	0.114	
0.003	0.128	0.031	0.067	0.029	0.069	0.071	0.043	0.107	0.120	
0.033	0.210	0.010	0.051	0.077	0.061	0.062	0.055	0.184	0.100	
0.022	0.256	0.025	0.068	0.094	0.062	0.083	0.104	0.131	0.200	
0.036	0.167	0.018	0.083	0.137	0.131	0.111	0.107	0.134	0.141	
0.021	0.200	0.024	0.057	0.073	0.088	0.090	0.084	0.141	0.130	
	0.180	0.003	0.036	0.052	0.068	0.069	0.063	0.120	0.109	
		1.8	20.1	29.2	37.6	38.6	35.2	67.0	60.9	
DATE: 6/24/98					INOC: 6/22/98					
DRUG: TBT					VIRUS: HSV-2					
					Specimen #5 TBT-IC50 = 0.5 µg/ml					

Column headings for the ELISA are culture control (CC) representing uninfected cell culture; Viral Control (VC), representing infected cell culture; 4-3-2-1-0.75-0.5-0.25-0.1 are viral infected cell cultures to which 4 to 0.1 µg/ml *Taxus Brevifolia* Tincture (TBT) has been added.

THEOREM

THEOREM

THEOREM